Findings

What do systematic reviews say?

5 questions · 5 findings · 4 reviews · Gut

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 60%High 2 · 40%

Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma

Chemotherapy probably leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).

1 finding from 1 review

Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
HR 0.66 [0.52, 0.83]
2 studies · 547 participants
Moderate

Overall survival · people with advanced gastric cancer

Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.37 [0.24, 0.55]
3 studies · 184 participants
Moderate

Overall survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table (subcomparison 1): chemotherapy or… leads to lower overall survival compared with BSC (high certainty).

1 finding from 1 review

Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma

Biological therapy leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).

1 finding from 1 review

Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
HR 0.55 [0.41, 0.73]
3 studies · 781 participants
High

Overall survival · advanced pancreatic cancer

Anti‐cancer therapy showed no clear difference in overall survival compared with best supportive care (moderate certainty).

1 finding from 1 review

Chemotherapy and radiotherapy for advanced pancreatic cancer 2018 · Cochrane Headline outcomes only
HR 1.08 [0.88, 1.33]
4 studies · 298 participants
Moderate